A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
A case series of hydroxychloroquine exacerbating the dermatomyositis rash
Dermatol Online J. 2023 Oct 15;29(5). doi: 10.5070/D329562407.ABSTRACTHydroxychloroquine (HCQ) is an antimalarial agent that is commonly used in the management of rheumatic skin disease. Few reports exist documenting exacerbation of dermatomyositis (DM) related to HCQ. Herein, we describe three adult patients with worsening DM cutaneous disease after starting HCQ and resolution or improvement with cessation. The time to exacerbation ranged from two weeks to nine months after the initiation of HCQ 400mg/day. Two of the three patients had antibodies to transcription intermediary factor 1γ (TIF1γ) and the other had antibodi...
Source: Dermatol Online J - March 13, 2024 Category: Dermatology Authors: Katelyn Rypka Michele Buonomo Connor Buechler Molly Benolken Adam Swigost Nikifor Konstantinov Kevin Gaddis Noah Goldfarb Source Type: research
